Hong Kong Actor Carlos Chan Accompanies His Mother to Shin-Yokohama Kato Clinic for Immunotherapy, Expresses Gratitude to Dr. Yoichi Kato
Renowned Hong Kong actor Carlos Chan recently accompanied his mother (“Mrs. Chan”) to the Shin-Yokohama Kato Clinic in Japan for continued immunotherapy. During this visit, he extended heartfelt thanks to the attending physician, Dr. Yoichi Kato, for his dedicated care and support. Dr. Kato commended Mr. Chan for his genuine love and devotion, describing him as a thoughtful and dutiful son.
Mrs. Chan began receiving immunocellular therapy at Dr. Kato’s clinic just over two months ago, leading to a marked improvement in her condition. She is now nearly fully recovered and will only require regular follow-up checkups in Hong Kong. Carlos Chan expressed deep appreciation for the positive outcome, emphasizing his commitment to following Dr. Kato’s guidance to ensure his mother’s continued well-being.
About Dr. Yoichi Kato (加藤洋一)
Dr. Yoichi Kato is a renowned Japanese oncologist and a pioneer in immunotherapy, recognized for his extensive research background and impressive clinical achievements:
- Impressive Research Credentials
From 1995 to 1999, Dr. Kato led the research and development of immunocellular therapy at Japan’s leading national institute, the National Cancer Center.
Through offering innovative treatment solutions to a significant number of cancer patients, he established a prominent reputation in Japan’s immunotherapy field.
- Shin-Yokohama Kato Clinic
In 2008, Dr. Kato founded the Shin-Yokohama Kato Clinic, combining cutting-edge immunocellular therapy with highly personalized patient care.
To date, the clinic has amassed a substantial number of clinical cases, showing remarkable efficacy in treating advanced-stage cancer. Statistics reveal that 68% of end-stage patients experienced considerable improvement, with 8% achieving complete tumor remission (CR).
- Treatment Philosophy and Future Vision
Dr. Kato advocates a patient-centric approach, emphasizing holistic medical care to enhance patients’ quality of life.
He envisions further expanding research and availability of immunocellular therapy, empowering more patients to benefit from this advanced treatment modality—ultimately aiming to improve cure rates and reduce recurrence risks.
